Observational Study on Patients With Hepatocellular Carcinoma (HCC)
NCT ID: NCT04021056
Last Updated: 2019-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3000 participants
OBSERVATIONAL
2011-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC
NCT05002452
Primary Hepatobiliary Cancer Cohort of Central China
NCT05520801
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
NCT04152356
Observational Study on Patients With Hepatobiliary Tumors
NCT04637048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 16 years;
* Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
* Good compliance with clinical treatment.
Exclusion Criteria
* Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
* HCC diagnosed after liver transplantation;
* Poor compliance or important data deficient.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jinlin Hou
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFHCC-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.